- Merck taps Thermo Fisher to manufacture COVID pill in Canada for global rollout push jkeenan Mon, 12/06/2021 - 11:11
- Merck's Hilleman Laboratories tees up $58M investment at new Singapore vaccine hub fkansteiner Mon, 12/06/2021 - 10:04
- Gilead recalls 2 lots of COVID-19 drug Veklury after finding glass particulates in vials fkansteiner Mon, 12/06/2021 - 08:43
- Novartis' Sandoz yanks one lot of deep vein thrombosis injectable after exposure to heat during shipping fkansteiner Fri, 12/03/2021 - 12:44
- Valneva stated that it is now focused on securing regulatory approvals for VLA2001 after the positive results from the Phase III trial. The firm also added that it The post EMA begins rolling review of Valneva’s Covid-19 vaccine...
- Preclinical data for GSK and Vir’s Xevudy suggests it retains activity against Omicron and all other variants of concern
- Pfizer CEO predicts annual jabs will be needed to maintain a ‘very high level of protection’ against COVID-19 and emphasises the need to vaccinate children
- Financial details of the deal have not been disclosed. This deal is part of Sanofi’s strategy to explore growth opportunities and build a vaccines pipeline. The transaction will The post Sanofi agrees to buy Austria-based Origimm...
- Amgen's Otezla notches win in genital psoriasis, snagging possible edge against forthcoming BMS rival fkansteiner Thu, 12/02/2021 - 10:02
- Leucid Bio taps Lonza's production expertise for a phase 1 CAR-T therapy trial jkeenan Thu, 12/02/2021 - 08:16
- Aspen Pharmacare, pursuing J&J vaccine license, aims to shore up local capacity and quash shot inequality in Africa fkansteiner Thu, 12/02/2021 - 07:59
- The Swiss biopharmaceutical group has acquired the Berlin-based diagnostics biotech after two decades of collaboration, expanding its PCR test portfolio
- The acquisition brings Origimm’s ORI-001 vaccine candidate against acne vulgaris into Sanofi’s vaccine pipeline, building its strength in mRNA technology
- In the first head-to-head comparison of the effectiveness of the Pfizer-BioNTech and Moderna COVID-19 vaccines, researchers examined the electronic health records of veterans who had received each vaccine. Both vaccines were highly...
- Today, Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), announced that it is working with Pfizer to create innovative, cloud-based solutions with the potential to improve how new medicines are developed,...
- Fujifilm socks $530M into U.K. vaccine, gene therapy and microbial production, creating 350 jobs fkansteiner Wed, 12/01/2021 - 16:45
- Sanofi aims to double vaccine sales by 2030, citing RSV and flu market expansion as key drivers esagonowsky Wed, 12/01/2021 - 13:51
- Moderna loses bid to invalidate vaccine delivery patents, teeing up potential infringement lawsuit fkansteiner Wed, 12/01/2021 - 12:42
- An interleukin-23 (IL-23) inhibitor, Risankizumab is intended to treat patients with Crohn’s disease who have shown insufficient response, lost response or are intolerant to biologic or conventional treatment. The post AbbVie seeks...
- AstraZeneca and Merck & Co (MSD) are together developing and commercialising Lynparza, a first-in-class PARP inhibitor. The sNDA was based on results obtained from the Phase III, The post US FDA grants priority review to...
- Amgen stalls Samsung's Enbrel biosim until 2029 in 2nd patent win of the year fkansteiner Wed, 12/01/2021 - 08:40
- As booster jab campaigns against COVID-19 are expanded in many countries, data from Israel backs up the benefits of being boosted
- The FDA looks set to authorise Merck’s molnupiravir after its advisory body recommended the antiviral treatment, while Pfizer’s Paxlovid may be next
- The first peer-reviewed study in North America examining the timing between the first and second doses of COVID-19 mRNA vaccines shows that a longer dose interval leads to a stronger immune response. The study is funded by the Government...
- GlaxoSmithKline (GSK) plc today launched Target the Future, an international, multi-year initiative dedicated to advancing innovation and addressing key needs in the multiple myeloma community. The programme will provide education on...
- Biogen takes another blow as appeal for Tecfidera patent revival falls short fkansteiner Tue, 11/30/2021 - 15:13
- French company Valneva and IDT Biologika have partnered to manufacture the former’s inactivated vaccine candidate, VLA2001, for Covid-19. The latest move follows an advance purchase agreement signed by The post Valneva, IDT Biologika...
- The move will enable Gilead to leverage AWS machine learning technologies and analytics to accelerate data-driven decision making across the organisation. The technologies are expected to support clinical The post Gilead Sciences selects...
- GSK's ViiV looks to future of injectable HIV treatment as long-acting PrEP decision looms fkansteiner Tue, 11/30/2021 - 11:10
- Aspen closes in on Africa license for Johnson & Johnson's COVID-19 vaccine fkansteiner Tue, 11/30/2021 - 09:05
- EpiPen rival Kaléo snapped up in $310M deal by investor group jkeenan Tue, 11/30/2021 - 08:47
- Regulators including the Food and Drug Administration (FDA) may treat Omicron-specific mRNA vaccines like seasonal flu vaccines, speeding up approval
- From May 23 to August 13, 2021, the Institut Pasteur, in partnership with the French National Health Insurance Fund (CNAM), Santé publique France and the Ipsos institute, conducted the fourth part of the ComCor epidemiological study on...
- COVID-19 tracker: Biden's winter plan includes tighter travel rules and free at-home tests elucas Mon, 11/29/2021 - 15:31
- The US Food and Drug Administration (FDA) has granted approval to Avacta Group’s Investigational New Drug (IND) application for AVA6000, a new form of doxorubicin. With this approval The post US FDA approves Avacta Group’s IND...
- Quell Therapeutics has raised $156m funding through an oversubscribed Series B funding round to advance its multi-modular engineered T regulatory (Treg) cell therapy pipeline and platform. SV Health The post Quell raises $156m Series B...
- Pfizer boosts Paxlovid manufacturing capacity as Merck's rival COVID pill hits surprise efficacy setback aliu Mon, 11/29/2021 - 11:38
- Amgen asks Supreme Court to take up its high-profile PCSK9 patent case against Sanofi and Regeneron fkansteiner Mon, 11/29/2021 - 11:15
- FDA deals another blow to Fennec's hearing loss treatment for pediatric cancer patients jkeenan Mon, 11/29/2021 - 10:31
- Novo Nordisk, Sanofi and Eli Lilly cut insulin prices and lose share in China's latest cost squeeze aliu Mon, 11/29/2021 - 10:27
- UK looks to shed $287M vaccine production facility to recoup costs, report says jkeenan Mon, 11/29/2021 - 09:24
- Former Insys execs ordered to pay $48.3M in restitution in Subsys opioid trial fkansteiner Mon, 11/29/2021 - 09:15
- A new variant of concern discovered in southern Africa is quickly spreading around the world, prompting government to take action
- Danish diabetes specialist Novo Nordisk cuts its growth forecast for 2022 following a value-based procurement deal with the Chinese government for its insulin products
- On 26 November 2021, WHO designated the variant B.1.1.529 a variant of concern, named Omicron, on the advice of WHO's Technical Advisory Group on Virus Evolution (TAG-VE). This decision was based on the evidence presented to the TAG-VE...
- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the use of Pfizer and BioNTech’s Covid-19 vaccine, Comirnaty, in children The post CHMP recommends use of Pfizer-BioNTech’s...
- Researchers in the US hope that the vaccine can stimulate the brain’s immune system to clear the amyloid plaques seen in Alzheimer’s
- An ‘unusual constellation of mutations’ in a new variant of the virus that causes COVID-19 has scientists worried that it could impact the efficacy of vaccines
- After hosting a virtual ceremony in 2020, this year’s awards returned to the Royal Lancaster London hotel
- Sanofi announced an equity investment of $180 million and a new strategic collaboration with Owkin comprised of discovery and development programmes in four exclusive types of cancer, with a total payment of $90 million for three years...